{{Rsnum
|rsid=11391
|Gene=HDAC2
|Chromosome=6
|position=113940851
|Orientation=minus
|GMAF=0.08494
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=HDAC2
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 0.9 | 26.5 | 72.6
| HCB | 0.7 | 16.8 | 82.5
| JPT | 0.0 | 19.6 | 80.4
| YRI | 0.0 | 0.7 | 99.3
| ASW | 0.0 | 5.3 | 94.7
| CHB | 0.7 | 16.8 | 82.5
| CHD | 0.0 | 14.7 | 85.3
| GIH | 1.0 | 28.7 | 70.3
| LWK | 0.0 | 1.8 | 98.2
| MEX | 0.0 | 17.2 | 82.8
| MKK | 0.0 | 0.6 | 99.4
| TSI | 2.0 | 20.6 | 77.5
| HapMapRevision=28
}}

Polymorphism within HDAC2 (Histone Deacetylase 2). 

Has been examined as a predictor of tumour recurrence in carcinoma patients, but unlike other SNPs analysed ( [[Rs1741981]] or [[Rs2547547]] ), did not correlate with recurrence-free survival.

==References==
{{PMID Auto
|PMID=20731616
|Title=Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}